(2013) Prognosis in diffuse large B-cell lymphoma. Cancer 119 , 1129-1131 /Lori S.Muffly, Sonali M.Smith. (2013) Prognosis in diffuse large B-cell lymphoma. Cancer 119 , 1129-1131 /Lori S. Muffly, Sonali M. Smith. (2013) Prognosis in diffuse large B-cell lymphoma. Cancer 119 , ...
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed
Aims: Anaplastic large cell lymphoma (ALCL) is classically considered a clinicopathological entity separate from other nodal mature T-cell lymphomas (TCL). Recently, the anaplastic lymphoma kinase (ALK) protein was shown to identify a subgroup of nodal ALCL with an excellent prognosis, whereas ALK-...
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. This study aimed to determine the prognostic significance of endoplasmic reticulum (ER) stress-related genes in DLBCL. ER stress-related genes were obtained from the molecular signatures database. Gene expression data and...
Introduction: Diffuse large B‐cell lymphoma (DLBCL) with follicular lymphoma (FL) component at diagnosis has been considered as one of transformed DLBCLs. The prognosis of transformed DLBCL has improved by use of rituximab‐contained therapy as same as de‐novo DLBCL. However, it is still ...
The molecular diversity exhibited by diffuse large B-cell lymphoma (DLBCL) is a significant obstacle facing current precision therapies. However, scoring using the International Prognostic Index (IPI) is inadequate when fully predicting the development of DLBCL. Reprogramming lipid metabolism is crucial ...
microRNAs have shown potential to be used as biomarkers for diagnosing and treating different types of cancers, though their application in doing so had yet to be determined.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy characterized by varied responses to treatment and prognoses. Understanding the metabolic characteristics driving DLBCL progression is crucial for developing personalized therapies. This
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclo- phosphamide, doxorubicin, vincristine and prednisone chemo- therapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015;56:1020-6....
Diffuse large B cell lymphoma (DLBCL) is an aggressive blood cancer known for its rapid progression and high incidence. The growing use of immunohistochemistry (IHC) has significantly contributed to the detailed cell characterization, thereby playing a crucial role in guiding treatment strategies for ...